Life Sciences Immunotherapy Platforms sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences Immunotherapy Platforms
1.1 - About Life Sciences Immunotherapy Platforms sector
Companies in the Life Sciences Immunotherapy Platforms category discover, engineer, and manufacture antibody, cell, and vaccine-based therapies that harness the immune system to treat cancer, infectious and inflammatory diseases. Strategic buyers in this space pair proprietary platforms with GMP production and clinical development, helping sponsors advance targeted, durable treatments, shorten time-to-clinic, and scale immunotherapies with reliable quality.
Typical capabilities span proprietary antibody engineering (including bispecifics and antibody‑drug conjugates), CAR‑T and off‑the‑shelf NK cell therapies, and T‑cell engager technologies with toxicity‑reducing designs. Many provide protein nanoparticle vaccine platforms with adjuvants, alongside CDMO services for process optimization, tech transfer, GMP manufacturing, and analytical testing. Some specialize in decentralized cell therapy manufacturing and DNA/cell engineering toolkits to accelerate translational programs.
Primary customers include clinical‑stage biopharma sponsors, oncology and infectious‑disease developers, and hospital‑based cell therapy centers. Outcomes typically include faster program progression to IND and pivotal trials, improved efficacy and response rates through precision immune modulation, reduced manufacturing risk and cost via scalable processes, and expanded patient access through near‑patient production and outpatient administration.
2. Buyers in the Life Sciences Immunotherapy Platforms sector
2.1 Top strategic acquirers of Life Sciences Immunotherapy Platforms companies
Emergent BioSolutions
HQ: United States
Website
- Description: Provider of specialized life-science countermeasures, offering vaccines, therapeutics, drug-device combination products and contract development and manufacturing services that address chemical, biological, radiological, nuclear, explosives, emerging infectious diseases and acute/emergency care threats for governments, first responders and community organizations in the US and Canada.
- Key Products:
- Process Development
- Optimization, and Scale Up: Provides process optimization, tech transfer, scale-up, formulation development, product characterization and analytics, advancing candidates to clinical and commercial phases
- Analytical Development and Testing Services: Provides customized phase-appropriate testing and support for each molecule from development through commercialization, ensuring regulatory compliance and high quality
- Drug Substance Manufacturing: Operates flexible suites for clinical to commercial production of plasma-derived therapies, polyclonal antibodies up to 1200L and other complex biological proteins
- Aseptic Fill/Finish Manufacturing: Uses Cytiva SA25 robotic isolator line for small- to mid-scale batches, filling vials, syringes or cartridges with in-house inspection, labeling and packaging.
- Rationale: Provider of process optimization and tech transfer, drug substance manufacturing for polyclonal antibodies, and Cytiva SA25 robotic isolator aseptic fill/finish.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Life Sciences Immunotherapy Platforms sector
M&A buyer group 1: Cancer Immunotherapy
47 companies
View group →
Description: Companies in Life Sciences Cancer Immunotherapy Therapeutics discover, engineer, and advance immune-based oncology treatments, spanning cell therapies, antibodies, ADCs, DNA medicines, and targeted inhibitors. They combine discovery platforms with clinical development and manufacturing to deliver precise tumor killing and durable responses, often addressing refractory cancers. Their value lies in translating immunobiology into approved and investigational therapies, improving patient survival while enabling partners to scale and commercialize cutting-edge modalities.
Precigen
- Type: N/A
- Employees: ●●●●●
- Description: Provider of biotechnology solutions focused on human gene therapy and gene editing, leveraging proprietary DNA-engineering technologies to control cellular functions and develop treatments such as CAR-T therapies for acute myeloid leukemia.
- Key Products:
- PRGN-3006 CAR-T Therapy: Investigational CAR-T treatment granted orphan drug status targeting acute myeloid leukemia by genetically engineering patient T-cells to attack cancer cells and potentially improve clinical outcomes
- Proprietary DNA Engineering Platform: Suite of complementary technologies that enables precise DNA-based control over cellular functions, supporting creation of diverse gene and cell therapies
- Human Gene Editing Programs: Focused research initiatives applying advanced gene-editing techniques to develop next-generation therapeutics for multiple diseases using Precigen’s engineered cell and gene platforms
🔒
🔒
🔒
View all 47 companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms in Life Sciences Immunotherapy Platforms sector
3.1 - Buyout funds in the Life Sciences Immunotherapy Platforms sector
2.2 - Strategic buyer groups for Life Sciences Immunotherapy Platforms sector
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Life Sciences Immunotherapy Platforms companies
4.2 - Public trading comparable groups for Life Sciences Immunotherapy Platforms sector
Valuation benchmark group 1: Platform Biotech and Therapeutics Companies
14 companies
View group →
Description: Public companies in this trading comparables group are platform biotechs and specialty therapeutics developers that leverage proprietary discovery, delivery, and immunology technologies to create multiple drug programs. They monetize through product sales, technology licensing, collaboration services, and royalties. They are grouped together as valuation benchmarks because their models blend commercial therapeutics with platform-derived fees, providing scalable pipelines and diversified cash flows tied to platform adoption.
argenx
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of antibody-based therapies focusing on treating severe autoimmune diseases, utilizing an innovative immunology platform to develop differentiated medicinal products for global markets.
- Key Products:
- Efgartigimod: An antibody therapy for immune disorders, improving symptom control in patients
- VYVGART: A first-in-class neonatal Fc receptor blocker for managing autoimmune conditions
- Immunology Innovation Program: Collaborates to accelerate novel target discovery and therapy development
- Clinical Trials: Executes global studies to validate efficacy and safety of therapeutic candidates
- Patient Support Services: Offers resources and guidance for patients using their therapies.
🔒
🔒
🔒
View all 14 companies in this group
Request Free Trial Now →
🔒
Revenue growth
Median
15.7%
2025E
16.0%
2026E
EBITDA margin
Median
28.2%
2025E
28.6%
2026E
Cash EBITDA margin
Median
27.6%
2025E
28.0%
2026E
EV/Revenue
Median
8.4x
2025E
6.8x
2026E
EV/EBITDA
Median
28.9x
2025E
24.4x
2026E
EV/Cash EBITDA
Median
29.0x
2025E
25.5x
2026E
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →